H/L Reference ranges Tests Results HE INSIDE **Pre-Analytical Screening U-Creatinine** 9.78 mmol/L Specific Gravity (U-Labstix) 1.02 5 pH (U-Labstix) Leucocytes (U-Labstix) Negative Nitrites(U-Labstix) Negative Haemoglobin (U-Labstix) Negative Blood (U-Labstix) Negative Protein (U-Labstix) Negative Glucose (U-Labstix) Negative Ascorbic Acid (U-Labstix) Negative Ketones (U-Labstix) Trace Urobilinogen (U-Labstix) Trace Bilirubin (U-Labstix) Trace Urine organic acids: Glycolysis and Kreb Cycle intermediates 2-Oxoglutaric acid/2-Ketoglutaric acid < 74.00 mmol/mol creat 1.15 Aconitic acid 31.07 Н 5.20 - 16.30 mmol/mol creat 82.43 Citric acid 87.00 - 639.00 L mmol/mol creat D/L-2-Hydroxyglutaric acid 8.07 mmol/mol creat < 52.00 < 16.40 mmol/mol creat **DL-Lactic acid** 2.88 0.20 - 1.70 Fumaric acid 0.76 mmol/mol creat Isocitric acid 14.19 < 119.10 mmol/mol creat Malic acid 1.74 < 5.30 mmol/mol creat Pyruvic acid 0.13 < 3.70 mmol/mol creat Succinic acid 9.13 2.50 - 13.50 mmol/mol creat Urine organic acids: Fatty acid oxidation intermediates 3-Hydroxybutyric acid 28.38 н < 6.40 mmol/mol creat Acetoacetic acid 10.97 < 24.90 mmol/mol creat Adipic acid 3.12 < 5.00 mmol/mol creat Ethylmalonic acid 3.55 < 4.00 mmol/mol creat Methylsuccinic acid BDL < 6.20 mmol/mol creat Sebacic acid 0.42 < 5.00 mmol/mol creat 0.96 < 1.90 mmol/mol creat Suberic acid Urine organic acids: Branched chain amino acid intermediates 2-Ethylhydracrylic-/2-Ethyl-3-OH-propionic acid н < 2.90 mmol/mol creat 8.48 2-Hydroxyisocaproic acid 0.06 < 0.39 mmol/mol creat 0.26 < 0.48 mmol/mol creat 2-Hydroxyisovaleric acid 2-Oxoisovaleric acid / 3-Methyl-2-oxobutyric acid 0.14 < 1.10 mmol/mol creat 3-Hydroxy-2-methylbutyric acid 1.93 < 6.20 mmol/mol creat 3-Hydroxyisobutyric acid 21.73 11.80 - 59.80 mmol/mol creat 8.28 3-Hydroxyisovaleric acid < 17.20 mmol/mol creat 3-Methyl-2-oxovaleric-/2-Keto-3-methylvaleric acid BDL < 4.80 mmol/mol creat 2.9 2.30 - 8.30 mmol/mol creat 3-Methylglutaconic acid 3-Methylglutaric acid 0.1 1.00 - 6.50 L mmol/mol creat 2-Ketoisocaproic acid/4-Methyl-2-oxovaleric acid 0.01 < 0.86 mmol/mol creat Malonic acid BDL < 3.10 mmol/mol creat Urine organic acids: Phenylalanine and Tyrosine intermedietes BDL < 0.76 mmol/mol creat Phenylpyruvic acid < 0.49 BDL 3-Phenyllactic acid mmol/mol creat 0.83 4-Hydroxyphenyllactic acid < 3.00 mmol/mol creat 4-Hydroxyphenylpyruvic acid BDL < 4.30 mmol/mol creat Mandelic acid 0.14 < 1.70 mmol/mol creat Homogentisic acid 0.11 < 2.80 mmol/mol creat BDL < 4.70 mmol/mol creat Succinylacetone Urine organic acids: Other Amino acid intermediates

Results:

BI@METRIX

| Tests | Results | H/L | Reference ranges | |
|---|------------|----------|------------------|----------------|
| Urine organic acids: Other Amino acid intermediate | es | | | |
| Glutaconic acid (Lysine Metabolism) | BDL | | < 3.10 | mmol/mol creat |
| N-Acetylaspartic acid (Aspartic Metabolism) | 1.25 | | < 7.00 | mmol/mol creat |
| Urine organic acids: Pyrimidine and Urea cycle interest | ermediates | | | |
| Orotic acid | 0.5 | | < 1.20 | mmol/mol creat |
| Thymine | BDL | | < 0.90 | mmol/mol creat |
| Uracil | 2.21 | _ | < 22.80 | mmol/mol creat |
| Uric acid | 119.63 | | 93.00 - 329.00 | mmol/mol creat |
| Urine organic acids: Detoxification markers | 221 | | | |
| 2-Hydroxybutyric acid | BDL | | < 6.90 | mmol/mol creat |
| 2-Methylhippuric acid | BDL | | < 13.50 | mmol/mol creat |
| Glyceric acid | 0.6 | | < 28.80 | mmol/mol creat |
| Glycolic acid | 8.61 | | < 78.10 | mmol/mol creat |
| N-2-Methylbutyrylglycine | 0.06 | | < 2.00 | mmol/mol creat |
| N-Butyrylglycine | BDL | | < 2.00 | mmol/mol creat |
| N-Hexanoylglycine | BDL | _ | < 2.00 | mmol/mol creat |
| N-Isobutyrylglycine | 0.63 | _ | < 3.80 | mmol/mol creat |
| N-Isovalerylglycine | 0.24 | _ | < 10.00 | mmol/mol creat |
| N-Phenylpropionylglycine | BDL | _ | < 0.60 | mmol/mol creat |
| N-Suberylglycine | BDL | _ | < 0.52 | mmol/mol creat |
| N-Tiglylglycine | 2.92 | н | < 2.00 | mmol/mol creat |
| N-3-Methylcrotonylglycine | BDL | _ | < 2.00 | mmol/mol creat |
| Oxalic acid | 83.87 | н | 1.11 - 33.34 | mmol/mol creat |
| Pyroglutamic acid | 7.24 | | < 24.90 | mmol/mol creat |
| Urine organic acids: Microbiome markers | | | | |
| 2,5-Furandicarboxylic acid | 0.4 | <u> </u> | < 5.40 | mmol/mol creat |
| 2-Hydroxyphenylacetic acid | 0.64 | | 1.40 - 3.70 | mmol/mol creat |
| 3,4-Dihydroxyphenylpropionic acid | 0.77 | н | < 0.35 | mmol/mol creat |
| 3,5-Dihydroxyphenylpropionic acid (DHPPA) | BDL | _ | < 0.38 | mmol/mol creat |
| 3-Hydroxyphenyl-3-hydroxypropionic acid (HPHPA) | 4.07 | _ | < 90.00 | mmol/mol creat |
| 3-Indoleacetic acid | 0.99 | _ | < 5.40 | mmol/mol creat |
| 3-Oxoglutaric acid/3-Ketoglutaric acid | BDL | | < 0.11 | mmol/mol creat |
| 4-Hydroxybenzoic acid | 6.8 | н | < 3.60 | mmol/mol creat |
| 4-Hydroxyhippuric acid | 4.63 | | < 30.00 | mmol/mol creat |
| 4-Hydroxyphenylacetic acid | 9.38 | | 1.40 - 14.60 | mmol/mol creat |
| 5-Hydroxymethyl-2-furoic acid (Sumiki's acid) | 0.7 | | < 1.70 | mmol/mol creat |
| Arabinose | 5.18 | | < 19.40 | mmol/mol creat |
| Benzoic acid | BDL | | < 6.50 | mmol/mol creat |
| Citramalic acid | 0.56 | | < 4.80 | mmol/mol creat |
| Hippuric acid | 202.97 | _ | 28.00 - 610.00 | mmol/mol creat |
| Hydrocinnamic acid/3-phenylpropionic acid | BDL | | < 0.219 | mmol/mol creat |
| N-2-Furanylcarbonylglycine | BDL | _ | < 8.40 | mmol/mol creat |
| p-Cresol | 15.22 | _ | < 118.90 | mmol/mol creat |
| Phenylacetic acid | BDL | _ | < 5.07 | mmol/mol creat |
| Tartaric acid | BDL | | < 64.40 | mmol/mol creat |
| Tricarballylic acid | 0.97 | н | < 0.44 | mmol/mol creat |
| Urine organic acids: Neurotransmitter intermediate | es | | | |
| 4-Hydroxybutyric acid (GABA metabolism) | BDL | _ | < 3.60 | mmol/mol creat |
| 5-Hydroxyindoleacetic acid (5-HIAA) | 1.22 | _ | < 5.80 | mmol/mol creat |
| Homovanillic acid (HVA) | 4.29 | | < 8.90 | mg/mmol creat |
| Quinurenic acid / Kynurenic acid | BDL | _ | < 4.10 | mmol/mol creat |
| | 0.51 | _ | < 15.10 | mmol/mol creat |
| Vanillactic acid | BDL | | < 0.19 | mmol/mol creat |
| VanillyImandelic acid (VMA) | 2.98 | н | < 2.80 | mmol/mol creat |
| HVA/VMA ratio | 1.44 | _ | 0.16 - 1.80 | |
| Quinolinic acid / 5-HIAA ratio | 0.41 | 1 | < 2.00 | |

| Tests | Results | H/L | Reference ranges | | | | |
|--|---------|-----|------------------|----------------|--|--|--|
| Urine organic acids: Nutritional markers | | | | | | | |
| 3-Hydroxy-3-methylglutaric acid (Q10) | 1.84 | | < 5.20 | mmol/mol creat | | | |
| 3-Hydroxypropionic acid (Biotin) | 2.43 | | < 11.80 | mmol/mol creat | | | |
| 4-Pyridoxic acid (Vit B6) | BDL | | < 7.50 | mmol/mol creat | | | |
| Ascorbic acid (Vit C) | 0.45 | L | 4.60 - 78.00 | mmol/mol creat | | | |
| Glutaric acid (Riboflavin) | 0.54 | L | 0.70 - 3.60 | mmol/mol creat | | | |
| Methylcitric acid (Biotin) | 1.17 | L | 1.20 - 1.80 | mmol/mol creat | | | |
| Methylmalonic acid (Vit B12) | 0.15 | | < 2.10 | mmol/mol creat | | | |
| Mevalonic acid (Q10) | BDL | | < 0.22 | mmol/mol creat | | | |
| N-Acetylcysteine (Glutathione cycle) | BDL | | < 0.13 | mmol/mol creat | | | |
| Pantothenic acid (Vit B5) | 0.59 | | < 4.40 | mmol/mol creat | | | |
| Xanthurenic acid (Vit B6) | BDL | | < 1.72 | mmol/mol creat | | | |

Technical Information:

on: Mahomani, Vutomi (V) Ms

GENERAL COMMENTS

BDL: The level of the reported metabolite is below the detection limit of the applied methodology. International reference ranges are currently applied.

South African population based reference ranges have not yet been established.

The uric acid level is determined via the chemical analyser platform with an enzyme based assay

*Essential amino acids.

NUTRITIONAL MARKER COMMENTS

Low or BDL 4-pyrodoxic acid, ascorbic acid, pantothenic, N-acetylcystine may be suggestive of a deficiency/insufficiency in these micronutrient

Elevated glutaric acid, methylcitric acid, 3-hydroxy-3-methyl-glutaric acid, 3-hydroxypropionic acid, mevalonic acid, xanthurenic acid are suggestive of corresponding micronutrient marker deficiency/insufficiency. A low level is insignificant.

Vorster, Chris (B.C.) Prof.

METABOLITE SPECIFIC INTERPRETATION

Aconitic acid is a Krebs cycle intermediate that is formed from citrate by the action of the aconitase enzyme. Aconitase is likely dependent on normal iron homeostasis and is extremely sensitive to oxidative damage. During hyperammonemia aconitic acid may be excreted in high amounts along with citrate and isocitrate due to the need for a counter anion. Aconitic acid, citrate and isocitrate is also frequently increased along with other Krebs cycle intermediates in patients with coenzyme Q10 deficiency and a mitochondrial respiratory chain insufficiencies.

Physiological conditions that may induce mild to moderate ketosis include fasting (typically longer than an overnight fast), strenuous exercise and a ketogenic diet. Medical conditions include diabetic ketoacidosis, alcoholic ketoacidosis, starvation, Addison's disease and various drugs & toxins. Rare metabolic diseases that may present with ketonuria as a prominent and isolated finding include some glycogen storage diseases and succinyl-CoA:3-ketoacid CoA transferase (SCOT)deficiency. The presence of hypoglycemia in the former and persistent ketosis & metabolic acidosis in the latter are important additional observations. These disorders cannot be excluded with metabolic testing however and will require genetic confirmation.

2-Ethylhydracrylic acid (2EHA) is formed when 2-oxo-3-methylvaleric acid is metabolised via the R pathway as opposed to the usual S pathway. This may occur due to an increased or ineffective isoleucine catabolism which is known to occur during illness or ketosis and have also been observed when dysbiosis is present. Mild and non-specific increases in isoleucine and its intermediates may also be present. A highly increased 2EHA excretion is associated with a number of inherited metabolic diseases including short/branched-chain acyl-CoA dehydrogenase deficiency, beta-ketothiolase deficiency, 2-methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency, propionic acidemia, methylmalonic acidemia, ethylmalonic encephalopathy and Barth

syndrome. In these instances, other characteristic organic acid markers are also typically present which is not the case here (PMID 15615815, 26115894).

Secondary hyperoxaluria may result due to an increased intake of oxalate or its precursors, low calcium or calcium sequestration in the gastrointestinal tract, or the loss of enteric bacteria. Spinach and rhubarb and also nuts, plums, chocolate, beetroot, strawberries and tofu are rich dietary sources. Excessive juicing of fruits and vegetables are prone to increase intake. Alternatively, excessive catabolism of exogenous or endogenous collagen produces 4hydroxyproline and eventually oxalate. Meat and especially gelatine are important exogenous sources of collagen. Vitamin C, glycine and ethylene glycol are additional precursors and may contribute substantially in cases of excessive supplementation or intoxication. The presence of calcium in the gastrointestinal tract greatly reduces the absorption of oxalate due to the formation of insoluble complexes. When calcium intake is low or when it is sequestrated in complexes with free fatty acids, as is the case in fat malabsorption, hyperoxaluria may be the result. Oxalobacter formigenes metabolises oxalate and loss of this bacterium (due to the use of antibiotics) may also increase oxalate excretion. Three inherited disorders of oxalate metabolism result in primary hyperoxaluria. Alanine-glyoxylate aminotransferase catalyses the conversion of glyoxylate to glycine. When this enzyme is deficient, primary hyperoxaluria type 1 (the most common type hyperoxaluria) result. The enzyme is dependent on pyridoxine and some of these patients respond to pyridoxine treatment. Hyperoxaluria, due to a pyridoxine deficiency, has however not been documented as a cause of hyperoxaluria.

3,4-Dihydroxyphenylpropionic acid (34DHPPA) and also 3,5-dihydroxyphenylpropionic acid (35DHPPA) results from gut microbial metabolism of polyphenolic compounds, especially caffeic acid, which are found in a variety of plant sources and coffee. Although it was initially thought that clostridial bacteria are primarily responsible for 34DHPPA production, it is now known that other bacteria can also produce it. Moreover, both 34DHPPA and 35DHPPA are now believed to have anti-inflammatory properties. Thus, while exceedingly high levels of 34DHPAA and/or 35DHPPA may be suggestive of gut dysbiosis, milder increases are likely due to an increased intake of polyphenolic compounds and may even be beneficial (PMID: 33238790, 19152477, 33470026, 31583990).

4-Hydroxybenzoic acid (4HBA) is likely derived from bacterial metabolism of tyrosine and dietary polyphenols and as such may be a marker of gut dysbiosis. After absorption it is activated in the liver by ATP dependent acid:CoA ligase and subsequently glycine conjugated by glycine N-acetyltransferase to form 4-hydroxyhippuric acid (4HHA). An increased 4HBA excretion therefore suggests and increased load or alternatively, a decreased capacity for glycine conjugation, particularly if 4HHA is inappropriately low. It has been proposed that 4HBA may disrupt the inner mitochondrial membrane and therefore 4HBA accumulation may be detrimental. It should be kept in mind however that 4HBA is also a key precursor in the coenzyme Q10 synthesis pathway.

Literature on tricarballylic acid (TCA) is scarce but available evidence indicates it is produced via bacterial reduction of trans-aconitate, which is derived from a variety of food sources. TCA is an inhibitor of the Krebs cycle and of aconitase in particular. It is a chelating agent and may therefore decrease divalent cation concentrations. It is also associated with fumonisin (FB) exposure. FBs are produced in maize by the fungal pathogen, Fusarium verticillioides. TCA is released when FB is hydrolysed. FB is a ceramide synthase inhibitor and has been implicated in carcinogenesis, neural tube defects and stunting in adults and children.

An increased secretion of vanillylmandelic acid (VMA) is traditionally associated with neurochromaffin tumours often with a profound increase in one or both markers even though normal values do not exclude the diagnosis. Activation of the pituitary adrenocorticotropic hormone (ACTH)-adrenal cortisol axis during physical or psychological stress is a source of moderate increases. VMA excretion may also be increased secondarily due to gut dysbiosis.

Disclaimer: Comprehensive information with regards to tests, methods in use, sample requirements, analyte coverage and expected turnaround times can be viewed at https://pliem.co.za/. It is the responsibility of the requesting clinician to order the correct tests given a particular clinical presentation. The laboratory can assist with test selection if required.